Platform trials evaluate the efficacy of multiple treatments, allowing for late entry of the experimental arms and enabling efficiency gains by sharing controls. The power of individual treatment-control comparisons in such trials can be improved by utilizing non-concurrent controls (NCC) in the analysis. We present the R-package NCC for the design and analysis of platform trials using non-concurrent controls. NCC allows for simulating platform trials and evaluating the properties of analysis methods that make use of non-concurrent controls in a variety of settings. We describe the main NCC functions and show how to use the package to simulate and analyse platform trials by means of specific examples
Platform trials offer a framework to study multiple interventions in one trial with the opportunity ...
Researchers, clinicians, policymakers and patients are increasingly interested in questions about th...
Clinical Trial (CT) simulation is used by academic research centers and pharmaceutical companies to ...
Presentation for the Adaptive Designs and Multiple Testing Procedures Workshop 2023 (https://admtp20...
Abstract: Background: Platform trials allow adding new experimental treatments to an on-going trial....
Platform trials are becoming increasingly popular within drug development, attracting interest by pa...
Background: Platform trials can evaluate the efficacy of several experimental treatments compared to...
Presentation for the EU-PEARL webinar on the use of non-concurrent controls in platform trials (http...
Platform trials evaluating multiple treatment arms against a shared control are an efficient alterna...
. Concurrent simulation (CS) has been used successfully as a replacement for serial simulation. Base...
International audienceIn this paper, we present the dfcomb R package for the implementation of a sin...
An adaptive platform trial (APT) is a multi-arm trial in the context of a single disease where treat...
WOS: 000372521500008PubMed ID: 27000291Background and objective: Non-compartmental analysis (NCA) ca...
Adaptive seamless phase II/III clinical trial designs allowing treatment selection at an interim ana...
This article summarizes the discussions from the American Statistical Association (ASA) Biopharmaceu...
Platform trials offer a framework to study multiple interventions in one trial with the opportunity ...
Researchers, clinicians, policymakers and patients are increasingly interested in questions about th...
Clinical Trial (CT) simulation is used by academic research centers and pharmaceutical companies to ...
Presentation for the Adaptive Designs and Multiple Testing Procedures Workshop 2023 (https://admtp20...
Abstract: Background: Platform trials allow adding new experimental treatments to an on-going trial....
Platform trials are becoming increasingly popular within drug development, attracting interest by pa...
Background: Platform trials can evaluate the efficacy of several experimental treatments compared to...
Presentation for the EU-PEARL webinar on the use of non-concurrent controls in platform trials (http...
Platform trials evaluating multiple treatment arms against a shared control are an efficient alterna...
. Concurrent simulation (CS) has been used successfully as a replacement for serial simulation. Base...
International audienceIn this paper, we present the dfcomb R package for the implementation of a sin...
An adaptive platform trial (APT) is a multi-arm trial in the context of a single disease where treat...
WOS: 000372521500008PubMed ID: 27000291Background and objective: Non-compartmental analysis (NCA) ca...
Adaptive seamless phase II/III clinical trial designs allowing treatment selection at an interim ana...
This article summarizes the discussions from the American Statistical Association (ASA) Biopharmaceu...
Platform trials offer a framework to study multiple interventions in one trial with the opportunity ...
Researchers, clinicians, policymakers and patients are increasingly interested in questions about th...
Clinical Trial (CT) simulation is used by academic research centers and pharmaceutical companies to ...